ANZCTR search results

This project “Strong Carers, Strong Communities” aims to test an empowerment approach to health service development through collaboration with Aboriginal carers of people with disabilities, frail aged and mental illness. The caregivers are supported to set the service development agenda and outcomes in a culturally secure and highly participatory manner, to build capacity and drive change. Partnerships will be created with stakeholders. Comparison of outcomes from this participatory method to usual practice with education will be evaluated. The collaborative approach can be utilised as a template for future community services. The hypothesis central to this research is that collaborative health and community services that commit to facilitating the empowerment of Aboriginal consumers will have a significantly greater impact on their health and well-being, as compared to the provision of education and regular service practice alone.

Aims: * To examine the effectiveness of NAC in reducing POCD (primary aim) * To investigate the effectiveness of NAC in reducing biomarkers of neuroinflammation and oxidative stress in the perioperative setting * To examine the correlation between cognition and biomarkers * To identify possible predictors of POCD Hypotheses: * The administration of NAC in a perioperative setting is more effective than placebo in reducing the severity of early POCD, as measured by performance changes on a neuropsychological battery (primary hypothesis) * The administration of NAC in a perioperative setting is more effective than placebo in reducing the severity of long term POCD * The administration of NAC in a perioperative setting is more effective than placebo in reducing the incidence of post operative delirium * The administration of NAC in a perioperative setting is more effective than placebo in reducing the incidence of post operative mood disorders * The administration of NAC in a perioperative setting is more effective than placebo in improving quality of life * The administration of NAC in a perioperative setting is more effective than placebo in improving post surgical pain * The administration of NAC in a perioperative setting is more effective than placebo in reducing serum levels of biomarkers of neuroinflammation and oxidative stress

This study will examine if there is a benefit of an online intervention for persons with bipolar diagnoses, and what components appear to be useful. Specifically, the study will examine (1) whether exposure to the MoodSwings 2.0 intervention results in decreased depression and manic symptoms, as measured by the Montgomery Asberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) respectively; and (2) whether there is an association between graduated levels of involvement (Level 1, 2, or 3) and resulting improvement. We expect that those assigned to the control condition (Level 1) will have fewer positive outcomes than those in Level 2 or 3.

Background: A ‘bougie’ may be less traumatic than the GlideScope-specific intubating stylet during videolaryngoscopy-guided intubation, but no comparative studies of bougies have been performed. Objective: To compare the Portex tracheal tube introducer (PTTI) and Frova intubating introducer (FII) used with the GlideScope videolaryngoscope in simulated difficult intubation.

The study is evaluating the effect of a complex intervention including education and logistical strategies, to promote uptake of school-based Human Papillomavirus (HPV) vaccination among adolescents in the Australian national School-Based Vaccination Program. Who is it for? We will recruit a random sample of Australian secondary schools to be part of this study; adolescents in these schools who are offered HPV vaccine as part of the national school vaccination program have the option to participate in our study. Trial details Schools participating in this trial will be randomly (by chance) divided into one of two groups. Schools who are in one group will deliver a complex intervention for promoting the uptake of the HPV vaccination among adolescents in a school-based program which consists of an adolescent intervention, a parent/adolescent decision aid, and logistical strategies. Prior to the first dose of the HPV vaccination, education is delivered by school personnel through the school in an interactive session. An educational magazine is given to students as take-home information designed by and for adolescents; a website and app providing information for students to access in and outside of school; and distraction/relaxation app for students to be used on vaccination day. A parent/adolescent HPV Decision Aid or a brief HPV information resource for parents and adolescents to use together is delivered to parents and adolescents at the time of the vaccination consent form. Logistical strategies include 1) guidelines for nurses and teachers regarding set-up of the vaccination room; 2) strategies to promote improved consent form return (reminders, direct mail-out to parents, incentives e.g. Classroom consent form return); 3) up to one additional vaccination visit to deliver mop-up vaccination to students incompletely vaccinated. Participants in the second group will receive the standard national school-based HPV vaccination program that takes place across all jurisdictions. This includes government funded HPV vaccination (three doses) for adolescents after parental/guardian consent has been granted. As part of this process parents/guardians receive a standard government brochure that provides information about HPV and HPV vaccination, and nurses follow standard state health department policy for delivery of vaccine in schools.

General practitioners (GPs) were randomised into four groups. Each viewed a video monologue of an actor-patient as he might present to his GP following a hospital admission with ten problems. GPs were provided with a medical record as well as a long or short discharge letter, which was available at time of viewing the video or one week later. GPs indicated if they would prescribe, refer, or order tests for the patient’s problems.A short or long hospital discharge summary enumerating the patient’s problems. Intervention: Discharge summary available at time of consultation or a week later. To determine the relationship between the timing and length of hospital discharge letters and the identification of ongoing patient problems by GPs Number of ongoing patient problems identified for management by the GPs.

Given that the recovery of patients with isolated hand burns that were able to be managed conservatively or with Biobrane has been shown to be rapid and the amount of physiotherapy intervention required was relatively low, it raises the question of whether any physiotherapy intervention is actually required. Could the same rapid recovery be seen with natural recovery and no physiotherapy intervention? In a healthcare setting where resources (e.g. time, staffing) are always a major consideration, the ability to focus our physiotherapy interventions on those patients who actually require these is essential. Therefore, the aim of the current study is to compare outcomes between those patients who receive standard physiotherapy and those who receive no physiotherapy in patients with isolated hand/forearm burns that are able to be treated conservatively or with Biobrane.

The study is evaluating the safety, tolerability, and immunogenicity of ABP 980 in healthy subjects compared with US Food and Drug Administration (FDA)-licensed trastuzumab and European Union (EU)-authorized trastuzumab. Who is it for? You may be eligible to join this study if you are healthy male, aged between 18 to 45 years of age (inclusive), and have a body mass index between 18.0 and 30.0 kg/m2 (inclusive) for non-Japanese subjects. To be enrolled as a Japanese subject, subjects must be either first- or second-generation Japanese and have a body mass index between 18.0 and 25.0 kg/m2. Trial details Participants in this study will be randomly (by chance) divided into one of three groups. Participants in one group will receive 6mg/kg of ABP 980 (440mg vial) intravenously once only. Participants in the second group will receive 6mg/kg2 of FDA-licensed trastuzumab (440mg vial) intravenously. Participants in the third group will receive 6mg/kg2 of EU-authorised trastuzumab (440mg vial) intravenously. All participants will be followed-up at 64 days post allocation to one of the three drugs used in this trial. Address: Nucleus Network Limited Centre for Clinical Studies (AMREP site) Level 5 Burnet Building 89 Commercial Road, Melbourne, Victoria 3004

The purpose of this study is to determine if integrated oncogeriatric care improves outcome in older patients who are receiving chemotherapy for cancer. Who is it for? You may be eligible to join this study if you are aged 70 years or above, have been diagnosed with cancer and are about to start chemotherapy (this includes cytotoxic chemotherapy, targeted therapy or immunotherapy). Study details. Participants in this study will be randomly (by chance) allocated to one of two treatment groups. Participants in one group will receive integrated oncogeriatric care. In addition to seeing their oncology doctors, participants receiving integrated oncogeriatric care will also have a comprehensive assessment and management by a geriatrician to identify problems early on and help co-ordinate care to support patients, their carers and their families better. Participants in the other group will receive standard oncology care and continue to see their oncology doctors for treatment of their cancer. Participants will be regularly assessed over 24 weeks by questionnaires to determine whether integrated oncogeriatric care improves quality of life, function, mood, nutrition, chemotherapy delivery, healthcare utilisation and healthcare costs.

This study aims to compare the efficacy of corticosteroid vs. autologous blood vs. sclerosant injection for the treatment of tennis elbow in order to see which treatment modality incurs the most benefit.